Uracil

Spécifications

66-22-8Numéro CAS

200-621-9Numéro CE

1H-pyrimidine-2,4-dioneNom IUPAC

C4H4N2O2Formule chimique

112.09 g/molMasse molaire

uracil; 66-22-8; pyrimidine-2,4(1H,3H)-dione; 2,4(1H,3H)-Pyrimidinedione; Pyrod; Hybar X; 2,4-Dioxopyrimidine; Pirod; 2,4-Pyrimidinedione; 1H-Pyrimidine-2,4-dione; 1,2,3,4-tetrahydropyrimidine-2,4-dione; DTXSID4021424; NSC-3970; SQ-6201; SQ-7726; SQ-8493; CHEBI:17568; BMS-205603-01; 56HH86ZVCT; NSC3970; DTXCID101424; 2, 4-Dioxopyrimidine; RefChem:6338; 2-hydroxy-4-(1H)-pyrimidione; 2-hydroxy-4-(3H)-pyrimidione; 4-hydroxy-2-(1H)-pyrimidione; 200-621-9; 2,4-Dihydroxypyrimidine; pyrimidine-2,4-diol; 2,4-Pyrimidinediol; 51953-14-1; Uracil [USAN]; RU 12709; MFCD00006016; 2-Hydroxy-4(3H)-pyrimidinone; NSC 3970; Ura; 2,4-Pyrimidinediol (9CI); CCRIS 3077; 2-Hydroxy-4(1H)-pyrimidinone; SQ 6201; SQ 7726; SQ 8493; BMS 205603-01; AI3-25470; Lamivudine impurity e; 4-Hydroxy-2(1H)-pyrimidinone; 66255-05-8; Lamivudine impurity e rs; Fluorouracil specified compound c; NCGC00181030-01; 4-Hydroxyuracil; CAS-66-22-8; Pyrimidine-2,4(1H,3H)-dione (Uracil); Uracil (8CI); Uracil [USAN:JAN]; 2(1H)-Pyrimidinone, 4-hydroxy-; 2(1H)-Pyrimidinone, 6-hydroxy-; 4(3H)-Pyrimidinone, 2-hydroxy-; EINECS 200-621-9; UNII-56HH86ZVCT; Uracyl; Urazil; 66224-60-0; 8h-uracil; hydroxypyrimidinone; Uracil (Standard); 2,6-Dioxypyrimidin; 2,4-Dioxypyrimidine; 144104-68-7; 2,4(1H,3H)-Pyrimidinedione (9CI); pyrimidine-2,4-dione; Uracil, 99%; 1ui0; Uracil (JAN/USAN); 2,3H)-Pyrimidinedione; 2,6-Dihydroxypyrimidine; URACIL [JAN]; URACIL [USP-RS]; URACIL [WHO-DD]; Lamivudine EP Impurity F; URACIL [MI]; URACIL [MART.]; bmse000187; bmse000940; CHEMBL566; Epitope ID:120356; NCIMech_000782; SCHEMBL8235; Fluorouracil impurity C CRS; Uracil, >=99.0%; pyrimidine, 2,4-dihydroxy-; SCHEMBL29730; SCHEMBL80962; SCHEMBL94310; 51953-19-6; MLS001304993; SCHEMBL144010; SCHEMBL151239; SCHEMBL537174; SCHEMBL877869; SCHEMBL925137; GTPL4560; orb1310972; SCHEMBL1050479; SCHEMBL5089507; SCHEMBL6286831; SCHEMBL6434097; SCHEMBL6434098; SCHEMBL7267501; SCHEMBL7335265; SCHEMBL9734266; SCHEMBL9779787; 2,4-(1h,3h)-pyrimidinedione; SCHEMBL10580164; SCHEMBL11607890; SCHEMBL13276278; SCHEMBL29525634; SCHEMBL31434533; HY-I0960R; Uracil, >=99.0% (T); 1,3-dihydropyrimidine-2,4-dione; HMS2234E19; HMS3264C13; HMS3373E18; HMS3652N05; HMS5082D06; Pharmakon1600-01502345; 4(1H)-Pyrimidinone, 2-hydroxy-; HY-I0960; NSC29742; ZAA89752; Tox21_112680; Tox21_201023; BDBM50549809; CCG-35866; EBC-13197; MSK000882; NSC-29742; NSC759649; s4177; SBB058492; STK301734; STL124066; AKOS000119989; AKOS002303991; Tox21_112680_1; CCG-213042; CS-W020104; DB03419; FU01843; NSC-759649; PS-5279; SB55489; SB55884; NCGC00181030-02; NCGC00247663-01; NCGC00258576-01; Uracil, Vetec(TM) reagent grade, 98%; NCI60_003718; SMR000752912; SY008943; DB-030518; DB-103964; DB-268940; DB-268966; DB-272084; DB-272202; LAMIVUDINE IMPURITY F [EP IMPURITY]; FLUOROURACIL IMPURITY C [EP IMPURITY]; LAMIVUDINE IMPURITY E [USP IMPURITY]; NS00002070; ST45061548; SW220239-1; U0013; U6901; EN300-17138; Uracil, suitable for cell culture, BioReagent; C00106; D00027; SBI-0053640.0002; AB00171810_03; AB00171810_04; AB00918623-05; AC-907/30002021; F036407; Q182990; BRD-K80129304-001-08-1; BRD-K80129304-001-09-9; Z56889474; F1796-0008; FLUOROURACIL SPECIFIED COMPOUND C [USP IMPURITY]; E2FC11E5-1887-46DF-B415-82313CE9B2BD; Uracil, United States Pharmacopeia (USP) Reference Standard; Uracil; Lamivudine EP Impurity F; Fluorouracil EP Impurity C; 2,4(1H,3H)-Pyrimidinedione; 2,4-Dihydroxypyrimidine; 2,4-Pyrimidinediol; Fluorouracil impurity C, European Pharmacopoeia (EP) Reference Standard; InChI=1/C4H4N2O2/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8; Uracil, Pharmaceutical Secondary Standard; Certified Reference MaterialSynonymes